Drug intelligence / Profile preview

K-252a

Development stage
Preclinical
Modality
Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Topical
01

Overview

**K-252a** is an indolocarbazole-based alkaloid and a staurosporine analog isolated from Nocardiopsis and Actinomadura species. It is a potent, broad-spectrum inhibitor of protein kinases, including protein kinase C (PKC), protein kinase A (PKA), protein kinase G (PKG), calcium/calmodulin-dependent kinase II (CaMKII), phosphorylase kinase, tropomyosin receptor kinases (Trk/NTRK family), myosin light-chain kinase, mixed-lineage protein kinase 3, FLT3 receptor tyrosine-protein kinase, and actin-regulating kinases. Its mechanism of action involves competitive inhibition at the ATP binding site of these kinases. At nanomolar concentrations it potently inhibits Trk receptors and blocks nerve growth factor signaling in neuronal cells. Preclinical research has explored its use as an antimicrobial agent and as a potential treatment for psoriasis; it also exhibits neuroprotective effects at low concentrations but can induce apoptosis by inhibiting cell cycle regulators such as Cdc2 and Cdc25[1][3][4][5][6][8].

Other names
k-252ak252ak 252aSF 2370SF2370SF-2370Antibiotic K 252aAntibiotic SF 2370
02

Targets

PHKA2 (Phosphorylase Kinase)PDE1 (Phosphodiesterase 1)PKA (Cyclic amp-dependent protein kinase)CAMK2D (Calcium/calmodulin-dependent protein kinase II delta)PKG (cGMP-dependent protein kinase I alpha)PKC (Protein kinase C family)NTRK1 (Tropomyosin-related receptor kinase A)MLCK (Myosin light chain kinase)MAPK family (MAPK family detailed)

Beyond the preview

Go deeper on K-252a.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on K-252a.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call